Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

30.12 +0.06 (+0.20%)
Streaming Delayed Price Updated: 10:19 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
What Analysts Are Saying About Genmab Stock ↗
 
Via Benzinga
News headline image
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
News headline image
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy? ↗
Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy? 
Via Chartmill
News headline image
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer ↗
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. 
Via Benzinga
News headline image
Breaking Down Genmab: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
Via Chartmill
News headline image
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗
NASDAQ:GMAB is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
News headline image
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
From Genmab
Via Business Wire
News headline image
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio? 
Via Benzinga
News headline image
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗
NASDAQ:GMAB, a growth stock which is not overvalued. 
Via Chartmill
News headline image
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via Business Wire
News headline image
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—a stock with solid growth prospects and a reasonable valuation. ↗
GENMAB A/S -SP ADR was identified as an affordable growth stock. NASDAQ:GMAB is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
A Closer Look at 10 Analyst Recommendations For Genmab ↗
 
Via Benzinga
News headline image
Preview: Genmab's Earnings ↗
 
Via Benzinga
News headline image
In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals. ↗
Take a closer look at GENMAB A/S -SP ADR , a remarkable value stock. NASDAQ:GMAB excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗
Uncover the potential of GENMAB A/S -SP ADR, a growth stock reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB. ↗
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
News headline image
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
News headline image
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
News headline image
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.